Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $350.31, for a total value of $700,620.00. Following the sale, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $1,401,240. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on REGN shares. Analysts at Zacks downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to an “underperform” rating in a research note on Tuesday. They now have a $316.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Finally, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $344.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.14% on Wednesday, hitting $350.01. 439,481 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $235.02 and a 52-week high of $354.79. The stock has a 50-day moving average of $325. and a 200-day moving average of $312.2. The company has a market cap of $35.138 billion and a price-to-earnings ratio of 100.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 5th. The company reported $2.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.15 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.